中国实验血液学杂志2024,Vol.32Issue(2) :625-629.DOI:10.19746/j.cnki.issn1009-2137.2024.02.045

MRD对急性髓系白血病预后评价作用的研究进展

Research Progress on the Prognostic Evaluation of MRD in Acute Myeloid Leukemia

刘恒 李子坚
中国实验血液学杂志2024,Vol.32Issue(2) :625-629.DOI:10.19746/j.cnki.issn1009-2137.2024.02.045

MRD对急性髓系白血病预后评价作用的研究进展

Research Progress on the Prognostic Evaluation of MRD in Acute Myeloid Leukemia

刘恒 1李子坚2
扫码查看

作者信息

  • 1. 兰州大学第一临床医学院
  • 2. 兰州大学第一医院血液科,甘肃兰州 730000
  • 折叠

摘要

急性髓系白血病(AML)是异质性极高的一组血液系统恶性肿瘤.虽然相当数量的AML患者经化疗、靶向治疗联合/不联合HSCT而获得长期生存,但是仍有部分患者难以达到缓解或缓解后早期复发,因此,细化风险分层并实现个体化治疗的预后指标具有重要意义.随着AML预后指标研究的日渐深入,预后分层也随之不断改进完善,由依赖MICM分型指标发展到联合治疗后MRD等疾病生物学特征指标的综合评价.本文综述了AML预后指标的发展及MRD对AML预后评价作用的研究进展,以帮助更好地识别不同风险的患者,有利于精准诊治方案的制订和实施.

Abstract

Acute myeloid leukemia(AML)is a highly heterogeneous group of malignant tumors in the blood system.Although many AML patients have achieved survive for a long time through chemotherapy and targeted therapy combined with/without HSCT,but some of them still be difficult to achieve remission or early relapse after remission.Therefore,refining risk stratification and achieving individualized treatment based on prognostic indicators is of great significance.As the research on prognostic indicators of AML deepens increasingly,the prognostic stratification has been continuously improved,from the MICM typing index to the comprehensive evaluation of biological disease characteristics such as MRD.This article reviews the development of prognostic indicators for AML and the research progress of MRD on AML prognosis evaluation to better identify patients with different risks and formulate and implement accurate diagnosis and treatment programs.

关键词

急性髓系白血病/微小残留病/进展

Key words

acute myeloid leukemia/measurable residual disease/progression

引用本文复制引用

基金项目

&&(2020-ZD-68)

出版年

2024
中国实验血液学杂志
中国病理生理学会

中国实验血液学杂志

CSTPCDCSCD北大核心
影响因子:0.988
ISSN:1009-2137
参考文献量35
段落导航相关论文